May 24, 2018
A key health ministry panel on May 23 backed approval of a slew of drugs including a breast cancer indication for AstraZeneca’s PARP inhibitor Lynparza (olaparib) and Chugai Pharmaceutical’s follicular lymphoma treatment obinutuzumab. Their official green light is expected in...read more